A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)
Status:
Withdrawn
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled study will evaluate the potential of
aleglitazar to reduce the risk of end stage renal disease and cardiovascular mortality in
patients with type 2 diabetes mellitus and chronic kidney disease. Patients will be
randomized to receive oral daily doses of aleglitazar or matching placebo. The anticipated
time on study treatment is approximately 3 years.